These effectors could arise naturally as the tumours develop, such as the T cells seen in many melanoma patients,2,63,64 or from intentional

immunization with tumour-associated antigens,2–4 or could even be T cells that have been expanded and even genetically modified in vitro and adoptively transferred.65,66 Hence, although we have shown effects of the fusion protein as a single agent, probably enhancing innate responses and the endogenous T-cell response, we hypothesize that the fusion protein find more would be even more effective in conjunction with immunization schemes. In this context there are a wide variety of innovative approaches for initiating anti-tumour cellular immune responses that show substantial promise (reviewed in refs 1 and 67) as well as recent clinical successes in patients with prostate cancer.68,69 The data presented here represent the first ‘proof of principle’ of the protease-activated cytokine approach using specific

inhibition. Importantly, the tethered cytokine strategy using specific inhibition is a platform technology that could be employed RG-7204 with different immunomodulatory agents to either promote (e.g. IL-12) or inhibit (IFN-β or IL-10) cellular immune responses. This would be particularly useful for cytokines that have potent anti-tumour effects like IL-12 but systemic side-effects limit their usefulness when given systemically.11,70 The scFv format is particularly flexible in this regard. An scFv could be developed against almost any target molecule given the extremely large antibody repertoire in the scFv library and could be made against immunomodulators such as chemokines where the receptor approach is not easily implemented. It is also important to consider that the cytokine environment in the tumour would probably be affected in a cascade fashion as the infiltrating cells change. As a result, it may be possible to alter the balance of cytokines from the generally suppressive environment of the tumour, rich in a variety of immunosuppressive factors, enzymes and cells,1,71–74 to one that is conducive to an ongoing immune response leading to the eradication of

tumours. GPCR & G Protein inhibitor The authors would like to thank Drs Edward Messing and Baek Kim for encouragement and helpful suggestions, Dr Robert Rose and Christopher Lane for helpful advice on insect cell expression of proteins, and Drs Barth, Leddy, Courtney, Simon, Valentino and Cohen for comments on the manuscript. This work was made possible by generous gifts from Steven and Alison Krausz and F.C. Blodgett. John Puskas, Denise Skrombolas and Abigail Sedlacek were supported by 5T32AI00728 from the National Institutes of Health. None of the authors involved with this work has any financial interests or any other conflict of interest to disclose. “
“The effects of the soluble forms of the endotoxin receptor molecules sMD-2 and sCD14 on bacterial growth were studied.